Odanacatib
{{Drugbox | IUPAC_name = (2S)-N-(1-cyanocyclopropyl)-4-fluoro-4-methyl- 2-{[(1S)-2,2,2-trifluoro-1-{4′-(methanesulfonyl)- [1,1′-biphenyl]-4-yl}ethyl]amino}pentanamide | image = Odanacatib.png | CAS_number = 603139-19-1 | CAS_supplemental = | ATC_prefix = | ATC_suffix = | ATC_supplemental = | PubChem = | DrugBank = | chemical_formula = | C=25 | H=27 | F=4 | N=3 | O=3 | S=1 | molecular_weight = 525.56 g/mol | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = }} Odanacatib (pINN; codenamed MK-0822) is an investigational treatment for osteoporosis. It is an inhibitor of cathepsin K,[1] an enzyme involved in bone resorption.
It is being developed by Merck & Co. As of May 2008, Merck is conducting phase III clinical trials.
References
- ↑ Gauthier JY, Chauret N, Cromlish W, Desmarais S, Duong le T, Falgueyret JP, Kimmel DB, Lamontagne S, Léger S, LeRiche T, Li CS, Massé F, McKay DJ, Nicoll-Griffith DA, Oballa RM, Palmer JT, Percival MD, Riendeau D, Robichaud J, Rodan GA, Rodan SB, Seto C, Thérien M, Truong VL, Venuti MC, Wesolowski G, Young RN, Zamboni R, Black WC. (2008). “The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K”. Bioorg Med Chem Lett. 18 (3): 923–928. doi:10.1016/j.bmcl.2007.12.047.
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH